BioRestorative Therapies Receives Notice of Allowance by the Japanese Patent and Trademark Office for a Patent Application Related to its ThermoStem® Program
15 mai 2023 07h00 HE
|
BioRestorative Therapies, Inc
--Upon issuance, patent will be the fourth Japanese patent to issue for the ThermoStem® program targeting obesity and metabolic disorders, including type 2 diabetes-- MELVILLE, N.Y., May 15, 2023 ...
BioRestorative Therapies and Northwell Health Enter into Agreement to Participate in the Company’s Phase 2 Clinical Trial
08 mai 2023 07h00 HE
|
BioRestorative Therapies, Inc
New York State’s largest health care provider will participate in BRTX’s clinical trial Expansive universe of patients and clinical sites from which to recruit high quality subjectsLeverage...
BioRestorative Therapies, Inc. to participate at the EF Hutton Global Conference May 10-11 in New York City
04 mai 2023 07h00 HE
|
BioRestorative Therapies, Inc
MELVILLE, NY., May 04, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies,...
BioRestorative Therapies Announces Completion of Patient Enrollment for Safety Run-In Component of its Phase 2 Clinical Study of BRTX-100
24 avr. 2023 07h00 HE
|
BioRestorative Therapies, Inc
--Clinical data from safety run-in scheduled to be released in second half of 2023.— MELVILLE, N.Y., April 24, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or...
BioRestorative Therapies to Seek FDA Approval to Expand the Clinical Application of BRTX-100
13 mars 2023 07h00 HE
|
BioRestorative Therapies, Inc
Bruder Consulting & Venture Group engaged to expand BRTX-100 clinical indication pipeline MELVILLE, N.Y., March 13, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”,...
BioRestorative Therapies to Participate at the 35th Annual ROTH MKM Conference on March 12 -14, 2023
07 mars 2023 06h30 HE
|
BioRestorative Therapies, Inc
Melville, NY., March 07, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative" or the "Company") (Nasdaq: BRTX), a clinical stage company focused on the development of...
BioRestorative Therapies Receives Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its ThermoStem® Program
02 mars 2023 07h30 HE
|
BioRestorative Therapies, Inc
--Notice of allowance will be the third US patent to issue from this ThermoStem® family targeting obesity and metabolic disorders, including type 2 diabetes-- MELVILLE, N.Y., March 02, 2023 ...
BioRestorative Therapies Announces Notice of Allowance by the European Patent Office for Patent Related to its ThermoStem® Program
08 févr. 2023 09h00 HE
|
BioRestorative Therapies, Inc
--Patent provides protection in key international markets for BioRestorative’s ThermoStem® program targeting obesity and metabolic disorders, including type 2 diabetes-- MELVILLE, N.Y., Feb. 08,...
BioRestorative Therapies Announces SBIR Phase I Grant to Explore the Therapeutic Effects of ThermoStem® Targeting Polycystic Ovary Syndrome as an Indication
06 déc. 2022 07h00 HE
|
BioRestorative Therapies, Inc
--Non-Dilutive Grant Funding to Support Development of Brown Adipose-Based Therapeutic Programs Directed at Polycystic Ovary Syndrome -- MELVILLE, N.Y., Dec. 06, 2022 (GLOBE NEWSWIRE) --...
BioRestorative Therapies Enters Agreement with Regenexx, Granting BRTX Exclusive License Rights for Intellectual Property Related to the Development and Commercialization of its BRTX-100® Disc Program to Treat Chronic Lumbar Disc Disease
05 déc. 2022 07h00 HE
|
BioRestorative Therapies, Inc
-- Intellectual Property Provides a Cell-Based Therapeutic Platform Designed to Target All Avascular Zones-- MELVILLE, N.Y., Dec. 05, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc....